programas cribado cancer


Nota Bibliográfica

Esta Nota es una recopilación de publicaciones (artículos, informes, libros) sobre cribado de cáncer resultado de una revisión no sistemática de la literatura.

Podéis dirigir vuestros comentarios o sugerencias sobre la Nota a:

Josep A Espinás. Pla Director d'Oncología de Catalunya.
Correo electrónico: Esta dirección electrónica esta protegida contra spam bots. Necesita activar JavaScript para visualizarla

Nota bilbiográfica cribado c cérvix 2012-07

** Ricerca del DNA di papillomavirus umano (HPV) come test primario per lo screening dei precursori del cancro del collo uterino. HTA report. Epidemiol Prev 2012;36(3/4 suppl 1):e1-72.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, et al. Clinical Human Papillomavirus Detection Forecasts Cervical Cancer Risk in Women Over 18 Years of Follow-Up. J Clin Oncol 2012 Jul 30.  DOI: 10.1200/JCO.2011.38.8389
Conclusion HPV testing to rule out cervical disease followed by Pap testing and possibly combined with the detection of HPV16 and HPV18 among HPV positives to identify those at immediate risk of CIN3+ would be an efficient algorithm for cervical cancer screening, especially in women age 30 years or older

Hendry M, Pasterfield D, Lewis R, Clements A, Damery S, Neal RD, et al. Are women ready for the new cervical screening protocol in England[quest] A systematic review and qualitative synthesis of views about human papillomavirus testing. Br J Cancer 2012 Jul 10;107(2):243-54.
Trimble CL. Preventing Human Papillomavirus Disease editorial. J Clin Oncol 2012 Jul 30.  DOI: 10.1200/JCO.2012.42.9787


Nota bilbiográfica cribado c cérvix 2012-06

Lönnberg SV, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiology Biomarkers & Prevention 2012 Jun 4.  DOI: 10.1158/1055-9965
Conclusions: Programme screening at the age of 25 is not associated with a reduced risk of cervical cancer in the following screening interval. Additional analyses are needed that also take opportunistic screening of women during the first rounds of organised screening into consideration. By contrast, screening yields substantial risk reductions in older ages at least up to the age of 60. This study also provides moderate indication of a long-lasting risk reduction associated with screening at the age of 65. Impact: Cervical cancer screening effectiveness is for the first time evaluated at different ages up to 65 with correction for self-selection bias of participation in organised screening

Trope A, Sjoborg KD, Nygard M, Roysland K, Campbell S, Alfsen GC, et al. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J Clin Microbiol 2012 Jun;50(6):1927-35.  PMC3372167  DOI: JCM.00265-12 [pii];10.1128/JCM.00265-12 [doi]
In conclusion, both positive HPV mRNA and DNA test results have a high enough long-term prediction of CIN2+ risk to consider referral to colposcopy as good practice when performed in delayed triage of women with ASCUS/LSIL cytology. In addition, the low CIN2+ risk among women with a negative Amplicor HPV test in our study confirms its safe use in a clinical setting


Screening: HPV testing for cervical cancer: the good, the bad, and the ugly

Castle PE. Screening: HPV testing for cervical cancer: the good, the bad, and the ugly. Nat Rev Clin Oncol 2010 Jul;7(7):364-5. 10.1038/nrclinonc.2010.96


The equivocal Pap test: its past, present, and future

Selvaggi SM. The equivocal Pap test: its past, present, and future. Diagn Cytopathol 2010 Jul;38(7):471-2.PMID:19941377 10.1002/dc.21277 [doi]


ACOG guidelines on cervical screening: a step in the right direction

Sasieni P, Castanon A, Cuzick J. ACOG guidelines on cervical screening: a step in the right direction. J Med Screen 2010 Jun 1;17(2):55-6


Página 6 de 13

web desarrollada y mantenida por :